U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07238868) titled 'An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy' on Nov. 16.
Brief Summary: CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.
Study Start Date: Aug. 14
Study Type: INTERVENTIONAL
Condition:
Focal Epilepsy
Intervention:
DRUG: CB03-154
All enrolled subjects will begin with a two-week course of CB03-154 at 10 mg QD. Upon demonstrating good tolerability, the dose will be increased to 20 mg QD and continued for up to two years.
Recruitment Status: RECRUITING
Sponsor: Shanghai Zhimeng Biopharma, I...